The prevalence of mutations in either KEAP1 or NFE2L2 (the gene encoding NRF2) is approximately 30% overall in NSCLC, with KEAP1 mutations occurring primarily in adenocarcinoma and NFE2L2 in squamous cell carcinoma [25,26]. This evidence concerns the gene NFE2L2 and squamous cell carcinoma.